Introduction
============

Irritable bowel syndrome is a functional gastrointestinal disorder characterised by abdominal pain or discomfort and accompanied by a change in bowel habit.[@ref1] The condition has a population prevalence of between 5% and 20% in community surveys.[@ref2] [@ref3] [@ref4] No known structural or anatomical explanation accounts for the pathophysiology of irritable bowel syndrome, and the exact cause remains unknown, although several mechanisms have been proposed. Altered gastrointestinal motility may contribute to the change in bowel habit reported by some patients,[@ref5] and a combination of smooth muscle spasm, visceral hypersensitivity, and abnormalities of central pain processing may explain the abdominal pain that is an essential part of the symptom complex.[@ref6] [@ref7]

Irritable bowel syndrome is a chronic relapsing and remitting condition,[@ref8] [@ref9] and a significant proportion of patients will consult their general practitioner with symptoms.[@ref9] [@ref10] Current guidelines for the management of irritable bowel syndrome in the United Kingdom recommend that the diagnosis should be made on clinical grounds alone, without the need for invasive investigations, unless alarm symptoms such as rectal bleeding or weight loss are present.[@ref11] [@ref12] As a result general practitioners are increasingly responsible for the initial management of patients with irritable bowel syndrome and are expected to refer only a minority to secondary care.

If they are to fulfil this role effectively, general practitioners need efficacious treatments that do not require monitoring and are cheap, safe, and readily available. This is particularly relevant at the present time as newer and more expensive drugs have either failed to show efficacy or been withdrawn from the market owing to concerns about serious adverse events. Traditionally, people with irritable bowel syndrome were instructed to increase their daily intake of dietary fibre, because of its potentially beneficial effects on intestinal transit time.[@ref13] When this failed, various types of smooth muscle relaxants and antispasmodics were used in an attempt to ameliorate symptoms, particularly pain and bloating.[@ref12] More recently, peppermint oil, which has been shown to have antispasmodic properties,[@ref14] has been available over the counter and has been used in the treatment of irritable bowel syndrome.

Whether any of these agents are effective in the treatment of irritable bowel syndrome is controversial. Results of randomised controlled trials are conflicting, and many have been underpowered to detect a difference between active treatment and control intervention. Systematic reviews have also come to different conclusions about the efficacy of the three treatments in irritable bowel syndrome.[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] As a result confusion exists as to the roles of these agents, with current management guidelines for irritable bowel syndrome making varying recommendations.[@ref11] [@ref12] [@ref23] [@ref24]

We carried out a systematic review and meta-analysis to determine the effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome.

Methods
=======

We searched the medical literature using Medline (1950 to April 2008), Embase (1980 to April 2008), and the Cochrane controlled trials register (2007). We considered randomised controlled trials of adults (\>16 years) with a diagnosis of irritable bowel syndrome based on a clinician's opinion or that met specific diagnostic criteria (Manning, Kruis score, Rome I, II, or III), combined with the results of investigations to exclude organic disease if trial investigators thought this necessary. The studies had to compare fibre, antispasmodics, and peppermint oil with placebo or no treatment. Participants were required to be followedup for at least one week, and studies had to report either a global assessment of cure or improvement of symptoms, or cure or improvement of abdominal pain, after treatment. This was preferably as reported by the patient, but could be documented by a doctor. If studies included patients with other functional gastrointestinal disorders, then we excluded these patients from our analyses if trial reporting allowed this, but if this was not possible we excluded the studies from the meta-analysis. We also considered as eligible for inclusion the first period of cross over randomised controlled trials. To allow steady state plasma concentrations of the agents to be achieved we considered one week as the minimum duration of treatment.

We identified studies on irritable bowel syndrome using the terms "irritable bowel syndrome" and "functional diseases, colon" (both as medical subject heading and free text terms), and "IBS, spastic colon, irritable colon", and "functional adj5 bowel" (as free text terms). These were combined using the set operator AND with studies identified with the terms: "dietary fibre", "cereals", "psyllium", "sterculia", "karaya gum", "parasympatholytics", "scopolamine", "trimebutine", "muscarinic antagonists", "butylscopolammonium bromide" (both as medical subject headings and free text terms), and the following free text terms: "bulking agent", "psyllium fibre", "fibre", "husk", "bran", "ispaghula", "wheat bran", "spasmolytics", "spasmolytic agents", "antispasmodics", "mebeverine", "alverine", "pinaverium bromide", "otilonium bromide", "cimetropium bromide", "hyoscine butyl bromide", "butylscopolamine", "peppermint oil", and "colpermin".

No language restrictions were applied. The lead reviewer evaluated the abstracts of papers identified by the initial search for appropriateness to the study question. Potentially relevant papers were obtained and evaluated in detail. Foreign language papers were translated when required. We hand searched abstract books of conference proceedings between 2001 and 2007 to identify potentially eligible studies. The reference lists of all identified relevant studies were used to carry out a recursive search of the literature. Two reviewers independently assessed articles using predesigned eligibility forms, according to eligibility criteria defined prospectively. Any disagreement between investigators was resolved by consensus.

Outcome assessment
------------------

The primary outcomes assessed were the efficacy of fibre, antispasmodics, and peppermint oil compared with placebo or no treatment on global symptoms of irritable bowel syndrome or abdominal pain after treatment. Secondary outcomes included efficacy according to specific type of fibre or antispasmodic, and adverse events as a result of treatment.

Data extraction
---------------

Two reviewers independently extracted data on to an Excel spreadsheet (XP professional; Microsoft, Redmond, WA) as dichotomous outcomes (persistent or unimproved global symptoms of irritable bowel syndrome, or persistent or unimproved abdominal pain). In addition we extracted the following clinical data for each trial: setting (primary, secondary, or tertiary care), number of centres, country, dose and duration of treatment, total number of adverse events reported, definition of irritable bowel syndrome used, primary outcome measure used to define improvement in symptoms or cure after treatment, method of generation of the randomisation schedule, method for allocation concealment, level of blinding, proportion of female patients, subtype of irritable bowel syndrome according to predominant stool pattern, and duration of follow-up. Data were extracted as intention to treat analyses where all dropouts are assumed to be treatment failures, whenever this was allowed by trial reporting. If this was not clear from the original article then we carried out an analysis on all patients with reported evaluable data.

Study quality
-------------

Two reviewers independently assessed study quality according to the Jadad scale.[@ref25] This records whether a study is described as randomised and double blind, the methods for generation of the allocation schedule and double blinding, and whether there is a description of dropouts during the trial.

Data synthesis and statistical analysis
---------------------------------------

We pooled data using a random effects model to give a more conservative estimate of the effect of individual treatments, allowing for any heterogeneity between studies.[@ref26] The effects of different interventions were expressed as a relative risk (95% confidence interval) of global symptoms of irritable bowel syndrome or abdominal pain persisting with fibre, antispasmodics, or peppermint oil compared with placebo or no treatment. For rare outcomes, such as adverse events, when no patients in one or both treatment arms had the outcome of interest in a single study, we added 0.5 to all four cells for the purposes of the analysis. From the reciprocal of the risk difference from the meta-analysis we calculated the number needed to treat and 95% confidence intervals. We used the I^2^ statistic, with a cut-off point of 25%,[@ref27] to assess heterogeneity between studies and the χ^2^ test with a P value \<0.10 to define a significant degree of heterogeneity. We planned to do sensitivity analyses a priori according to type of fibre or antispasmodic, predominant stool pattern of patients, and study quality according to the Jadad scale. If adverse events were statistically significantly increased with active treatment we calculated the number needed to harm and a 95% confidence interval using the formula: number needed to harm=1/(1--relative risk)×control adverse event rate.

We used Review Manager version 4.2.8 (Nordic Cochrane Centre, Copenhagen, Denmark) and StatsDirect version 2.4.4 (Sale, Cheshire, England) to generate forest plots of pooled relative risks and risk differences for primary and secondary outcomes with 95% confidence intervals. We used the Egger and Begg tests to assess funnel plots for evidence of publication bias.[@ref28]

Results
=======

The search strategy generated 615 citations, of which 101 were potentially relevant and retrieved for assessment (fig 1[](#fig1){ref-type="fig"}). Of these, 66 were excluded for various reasons, leaving 35 eligible randomised controlled trials; nine compared fibre with placebo or no treatment,^w1-w9^ 19 compared antispasmodics with placebo,^w10-w28^ four compared peppermint oil with placebo,^w29-w32^ and three compared both fibre and antispasmodics with placebo.^w33-w35^

![**Fig 1** Flow diagram of studies in systematic review](fora583237.f1){#fig1}

Fibre
-----

Twelve trials compared fibre with placebo or, in one instance, a low fibre diet,^w3^ totalling 591 patients with irritable bowel syndrome.^w1-w9\ w33-w35^ The proportion of women in the trials ranged between 20% and 90%. Only three studies reported on subtype of irritable bowel syndrome according to predominant stool pattern.^w1\ w4\ w6^ Two recruited only patients with predominant constipation,^w1\ w4^ and in the other trial 49% of patients had predominant constipation.^w6^ Table 1[](#tbl1){ref-type="table"} shows the characteristics of the studies. Five studies used bran,^w1-w3\ w7\ w34^ six used ispaghula husk,^w5\ w6\ w8\ w9\ w33\ w35^ and one used "concentrated" fibre of an unspecified type.^w4^ Seven of the studies scored 4 or more on the Jadad scale.^w2\ w4-w6\ w8\ w9\ w33^ None reported the method of allocation concealment.

###### 

 Characteristics of randomised controlled trials of fibre versus placebo or no treatment in irritable bowel syndrome

  Study                 Country    Setting          Diagnostic criteria for irritable bowel syndrome   Criteria to define symptom improvement after therapy                         Sample size   Fibre type                                            Duration of therapy   Jadad score
  --------------------- ---------- ---------------- -------------------------------------------------- ---------------------------------------------------------------------------- ------------- ----------------------------------------------------- --------------------- -------------
  Soltoft 1976^w2^      Denmark    Tertiary care    Clinical diagnosis and investigations              Patient reported improvement in global symptoms                              59            Miller's bran 30 g per day                            6 weeks               4
  Manning 1977^w3^      England    Tertiary care    Clinical diagnosis and investigations              Any decrease in patient reported percentage of days with pain                26            Bran 20 g per day (wheat bran or whole wheat bread)   6 weeks               3
  Ritchie 1979^w33^     England    Tertiary care    Clinical diagnosis and investigations              Patient reported improvement in global symptoms (doctor required to agree)   24            Ispaghula husk two sachets per day                    3 months              4
  Longstreth 1981^w9^   USA        Secondary care   Clinical diagnosis                                 Patient reported improvement in global symptoms                              77            Metamucil 6.4 g per day                               8 weeks               4
  Arthurs 1983^w8^      Ireland    Secondary care   Clinical diagnosis                                 Doctor reported improvement in global symptoms                               78            Ispaghula husk two sachets per day                    4 weeks               4
  Nigam 1984^w35^       India      Secondary care   Clinical diagnosis and investigations              Patient reported improvement in global symptoms (doctor required to agree)   42            Ispaghula husk (dose unclear)                         12 weeks              3
  Kruis 1986^w34^       Germany    Tertiary care    Clinical diagnosis and investigations              Patient reported improvement in global symptoms                              80            Wheat bran 15 g per day                               16 weeks              2
  Lucey 1987^w7^        England    Tertiary care    Manning criteria and investigations                Any decrease in global symptom score                                         28            Wheat bran biscuits 15.6 g per day                    3 months              3
  Prior 1987^w6^        England    Tertiary care    Clinical diagnosis and investigations              Patient reported absence of abdominal pain                                   80            Ispaghula husk three sachets per day                  12 weeks              4
  Jalihal 1990^w5^      India      Secondary care   Clinical diagnosis and investigations              Patient reported improvement in global symptoms                              20            Ispaghula husk 30 g per day                           4 weeks               4
  Fowlie 1992^w4^       Scotland   Tertiary care    Clinical diagnosis and investigations              Patient reported improvement in global symptoms                              49            4.1 g of unspecified fibre per day                    12 weeks              4
  Rees 2005^w1^         England    Tertiary care    Rome I criteria and investigations                 Patient reported improvement in global symptoms                              28            Wheat bran 10 to 20 g per day                         12 weeks              1

Overall, 155 of 300 (52%) patients assigned to fibre had persistent or unimproved symptoms after treatment compared with 168 of 291 (57%) allocated to placebo or a low fibre diet (relative risk 0.87, 95% confidence interval 0.76 to 1.00, P=0.05), with no statistically significant heterogeneity detected between studies (I^2^=14.2%, P=0.31; fig 2[](#fig2){ref-type="fig"}). The number needed to treat with fibre to prevent one patient with persistent symptoms was 11 (95% confidence interval 5 to 100). The funnel plot showed no statistically significant asymmetry (Egger test, P=0.84), suggesting no evidence of publication bias. When only the seven studies scoring 4 or more on the Jadad scale were considered in the analysis the treatment effect for fibre was no longer statistically significant (relative risk of persistent symptoms 0.90, 0.75 to 1.08).^w2\ w4-w6\ w8\ w9\ w33^

![**Fig 2** Forest plot of randomised controlled trials of fibre versus placebo or low fibre diet in irritable bowel syndrome. Events are number of patients with either global symptoms of irritable bowel syndrome or abdominal pain unimproved or persistent after treatment](fora583237.f2){#fig2}

### Bran

Five studies compared bran with placebo or a low fibre diet in a total of 221 patients.^w1-w3\ w7\ w34^ Only one study scored 4 or more on the Jadad scale.^w2^ Sixty two of 114 (54%) patients assigned to bran had persistent symptoms after treatment compared with 58 of 107 (54%) allocated to placebo or a low fibre diet. Bran had no significant effect on irritable bowel syndrome (relative risk of persistent or unimproved symptoms 1.02, 0.82 to 1.27; fig 2[](#fig2){ref-type="fig"}), with no statistically significant heterogeneity detected between studies (I^2^=0%, P=0.91), and no evidence of funnel plot asymmetry (Egger test, P=0.28).

### Ispaghula

Six studies randomised 321 patients to ispaghula or placebo.^w5\ w6\ w8\ w9\ w33\ w35^ Eighty three of 161 (52%) patients allocated to ispaghula had persistent symptoms after treatment compared with 103 of 160 (64%) receiving placebo. Ispaghula was effective in treating irritable bowel syndrome (relative risk of persistent or unimproved symptoms 0.78, 0.63 to 0.96; fig 2[](#fig2){ref-type="fig"}), with statistically significant heterogeneity detected between studies (I^2^=34.4%, P=0.18). The number needed to treat with ispaghula to prevent one patient having persistent symptoms was 6 (3 to 50). No evidence of funnel plot asymmetry was found (Egger test, P=0.43). Five of the six studies using ispaghula scored 4 or more on the Jadad scale.^w5\ w6\ w8\ w9\ w33^ When only these studies were considered in the analysis the treatment effect for ispaghula was no longer statistically significant (relative risk of persistent or unimproved symptoms 0.86, 0.74 to 1.01, P=0.06), with no statistically significant heterogeneity detected between studies (I^2^=2.6%, P=0.39).

### Adverse events

Data on the total number of adverse events were provided by only four trials.^w4\ w6\ w34\ w35^ These trials evaluated 251 patients, but as the number of adverse events was small the data were not pooled. A total of three patients receiving fibre reported adverse events compared with two in the placebo arms.

Antispasmodics
--------------

Twenty two studies compared 12 different antispasmodics with placebo in 1778 patients.^w10-w28\ w33-w35^ The proportion of women in each trial ranged from 39% to 83%. Six studies reported on subtype of irritable bowel syndrome according to predominant stool pattern.^w11\ w12\ w14\ w15\ w19\ w24^ One study recruited patients only with predominant constipation,^w15^ and in the remaining five studies between 22% and 64% of patients had predominant constipation. Table 2[](#tbl2){ref-type="table"} shows the characteristics of the studies. None of the trials reported the method of allocation concealment. Four trials used otilonium,^w16\ w23\ w25\ w26^ three cimetropium,^w11-w13^ three hyoscine,^w10\ w33\ w35^ three pinaverium,^w22\ w24\ w27^ two trimebutine,^w15\ w20^ one trimebutine and rociverine,^w14^ and one each of alverine,^w18^ dicycloverine (dicyclomine),^w21^ mebeverine,^w34^ pirenzipine,^w17^ prifinium,^w19^ and propinox.^w28^

###### 

 Characteristics of randomised controlled trials of antispasmodics versus placebo or no treatment in irritable bowel syndrome

  Study                   Country        Setting                       Diagnostic criteria for irritable bowel syndrome   Criteria to define symptom improvement after therapy                                                                                      Sample size   Antispasmodic and dose                                                       Duration of therapy   Jadad score
  ----------------------- -------------- ----------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------------------------------------------------------------------- --------------------- -------------
  Levy 1977^w22^          France         Secondary care                Clinical diagnosis and investigations              Improvement in global symptoms (unclear whether patient reported)                                                                         50            Pinaverium 50 mg three times daily                                           15 days               3
  Moshal 1979^w15^        South Africa   Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in abdominal pain                                                                                            20            Trimebutine 200 mg three times daily                                         4 weeks               4
  Piai 1979^w19^          Italy          Tertiary care                 Clinical diagnosis and investigations              Physician reported improvement in global symptoms                                                                                         18            Prifinium bromide 30 mg three times daily                                    3 weeks               4
  Ritchie 1979^w33^       England        Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in global symptoms (doctor required to agree)                                                                24            Hyoscine 10 mg four times daily                                              3 months              4
  D'Arienzo 1980^w23^     Italy          Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           28            Otilonium 20 mg three times daily                                            4 weeks               3
  Fielding 1980^w20^      Ireland        Secondary care                Clinical diagnosis and investigations              Physician reported improvement in global symptoms                                                                                         60            Trimebutine 200 mg three times daily                                         6 months              3
  Delmont 1981^w27^       France         Secondary care                Clinical diagnosis and investigations              Physician reported improvement in global symptoms                                                                                         60            Pinaverium (dose unclear) one tablet three times daily                       30 days               4
  Page 1981^w21^          Unclear        Primary and secondary care    Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           97            Dicycloverine (dicyclomine) 40 mg four times daily                           2 weeks               4
  Baldi 1983^w25^         Italy          Secondary care                Clinical diagnosis and investigations              Decrease in patient reported abdominal pain score                                                                                         30            Otilonium 40 mg three times daily                                            4 weeks               4
  Nigam 1984^w35^         India          Secondary care                Clinical diagnosis and investigations              Patient reported improvement in global symptoms (doctor required to agree)                                                                42            Hyoscine (dose unclear)                                                      12 weeks              3
  Ghidini 1986^w14^       Italy          Secondary care                Clinical diagnosis and investigations              Patient reported efficacy of treatment                                                                                                    90            Trimebutine 100 mg three times daily or rociverine 20 mg three times daily   60 days               3
  Kruis 1986^w34^         Germany        Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           80            Mebeverine 100 mg four times daily                                           16 weeks              4
  Virat 1987^w24^         France         Secondary care                Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           78            Pinaverium 50 mg three times daily                                           1 week                2
  Centonze 1988^w11^      Italy          Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           48            Cimetropium 50 mg three times daily                                          6 months              4
  Gilvarry 1989^w17^      Ireland        Secondary care                Clinical diagnosis and investigations              Doctor reported improvement in global symptoms                                                                                            24            Pirenzipine 50 mg twice daily                                                4 weeks               4
  Passaretti 1989^w13^    Italy          Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           40            Cimetropium 50 mg three times daily                                          1 month               4
  Dobrilla 1990^w12^      Italy          Secondary care                Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           70            Cimetropium 50 mg three times daily                                          3 months              4
  Schafer 1990^w10^       Germany        Primary and secondary care    Clinical diagnosis and investigations              Improvement in global symptoms assessed by diary cards                                                                                    360           Hyoscine 10 mg three times daily                                             4 weeks               3
  Castiglione 1991^w26^   Italy          Tertiary care                 Clinical diagnosis                                 Improvement in global symptoms (unclear whether patient reported)                                                                         60            Otilonium (dose and number of tablets unclear)                               1 month               2
  Pulpeiro 2000^w28^      Argentina      Tertiary care                 Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                                                           75            Propinox (dose and number of tablets unclear)                                4 weeks               3
  Glende 2002^w16^        Italy          Secondary and tertiary care   Rome I criteria                                    Decrease in patient reported symptoms (evaluated on a 4 point ordinal scale) of one unit in at least one symptom for at least two weeks   317           Otilonium 40 mg three times daily                                            15 weeks              3
  Mitchell 2002^w18^      UK             Secondary and tertiary care   Rome II criteria and investigations                Improvement in wellbeing from validated diary cards                                                                                       107           Alverine 120 mg three times daily                                            12 weeks              5

In total, 350 of 905 (39%) patients assigned to antispasmodics had persistent symptoms after treatment compared with 485 of 873 (56%) allocated to placebo (relative risk 0.68, 95% confidence interval 0.57 to 0.81), with statistically significant heterogeneity detected between studies (I^2^=62.6%, P\<0.001; fig 3[](#fig3){ref-type="fig"}). The number needed to treat to prevent symptoms persisting in one patient was 5 (95% confidence interval 4 to 9). The Egger test suggested evidence of funnel plot asymmetry (P=0.03), but this seemed to be driven by a single small study; the Begg test did not confirm asymmetry (P=0.25). The treatment effect in favour of antispasmodics remained when only the 12 trials that scored 4 or more on the Jadad scale were considered in the analysis (relative risk of persistent symptoms 0.65, 0.48 to 0.89),^w11-w13\ w15\ w17-w19\ w21\ w25\ w27\ w33\ w34^ although the heterogeneity observed between studies (I^2^=70.2%, P=0.0001) persisted and there was evidence of publication bias (Egger test, P=0.007).

![**Fig 3** Forest plot of randomised controlled trials of antispasmodics versus placebo in treatment of irritable bowel syndrome. Events are number of patients with either global symptoms of irritable bowel syndrome or abdominal pain unimproved or persistent after treatment. See bmj.com for individual tests for heterogeneity and for overall effect](fora583237.f3){#fig3}

The effect of different antispasmodics on symptoms of irritable bowel syndrome was examined separately. Four trials used otilonium in 435 patients.^w16\ w23\ w25\ w26^ Symptoms persisted in 111 of 216 (51%) patients assigned to otilonium compared with 155 of 219 (71%) of those receiving placebo (relative risk 0.55, 0.31 to 0.97, I^2^=59.5%), and a number needed to treat of 4.5 (95% confidence interval 3.0 to 10.0). Three trials used cimetropium,^w11-w13^ with 15 of 79 (19%) patients randomised to cimetropium having persistent symptoms after treatment compared with 42 of 79 (53%) receiving placebo (relative risk 0.38, 0.20 to 0.71, I^2^=37.2%). The number needed to treat with cimetropium was 3.0 (2.0 to 12.5). Three studies randomised 426 patients to hyoscine or placebo.^w10\ w33\ w35^ Symptoms persisted in 63 of 215 (29%) patients receiving hyoscine compared with 97 of 211 (46%) allocated to placebo (relative risk 0.63, 0.51 to 0.78, I^2^=0%), with a number needed to treat of 3.5 (2.0 to 25.0). Three trials used pinaverium in 188 patients.^w22\ w24\ w27^ Symptoms persisted in 26 of 94 (28%) patients assigned to pinaverium compared with 57 of 94 (61%) receiving placebo (relative risk 0.47, 0.33 to 0.67, I^2^=0%), and a number needed to treat of 3 (2 to 5). Three trials, totalling 140 patients, studied the effect of trimebutine.^w14\ w15\ w20^ Twenty eight of 70 (40%) patients assigned to trimebutine had persistent symptoms compared with 27 of 70 (39%) allocated to placebo (relative risk 1.08, 0.72 to 1.61, I^2^=0%). The relative risk of persistent symptoms in the single trials that used other antispasmodics were: mebeverine 1.25 (0.99 to 1.58), alverine 0.85 (0.60 to 1.22), dicycloverine 0.65 (0.45 to 0.95), pirenzipine 1.17 (0.56 to 2.45), prifinium 0.50 (0.18 to 1.40), propinox 1.23 (0.30 to 5.13), and rociverine 1.10 (0.55 to 2.19).

### Adverse events

Thirteen studies reported a total number of adverse events in 1379 patients.^w10-w16\ w18\ w20\ w21\ w25\ w27\ w34^ Overall, 101 of 704 (14%) patients assigned to antispasmodics experienced adverse events compared with 62 of 675 (9%) allocated to placebo. The commonest adverse events were dry mouth, dizziness, and blurred vision, but none of the trials reported any serious adverse events. The relative risk of experiencing adverse events with antispasmodics compared with placebo was 1.62 (95% confidence interval 1.05 to 2.50), with statistically significant heterogeneity detected between studies (I^2^=37.9%, P=0.07), but no evidence of publication bias (Egger test, P=0.53). The number needed to harm with antispasmodics was 17.5 (7.0 to 217.0).

Peppermint oil
--------------

Four studies compared peppermint oil with placebo in 392 patients.^w29-w32^ The proportion of women in each trial ranged from 40% to 76%. Only one study reported on disease subtype according to stool pattern and recruited 25% of patients with predominant constipation and 75% with predominant diarrhoea.^w31^ Table 3[](#tbl3){ref-type="table"} shows the characteristics of the studies. None of the trials reported the method of allocation concealment.

###### 

 Characteristics of randomised controlled trials of peppermint oil versus placebo in irritable bowel syndrome

  Study                Country   Setting          Diagnostic criteria for irritable bowel syndrome   Criteria to define symptom improvement after therapy                                                        Sample size   Dose of peppermint oil             Duration of therapy   Jadad score
  -------------------- --------- ---------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------- ---------------------------------- --------------------- -------------
  Lech 1988^w29^       Denmark   Secondary care   Clinical diagnosis and investigations              Patient reported improvement in global symptoms                                                             47            200 mg three times daily           4 weeks               3
  Liu 1997^w30^        Taiwan    Secondary care   Clinical diagnosis and investigations              Patient reported improvement in abdominal pain                                                              110           187 mg three or four times daily   1 month               4
  Capanni 2005^w32^    Italy     Secondary care   Rome II                                            Improvement in global symptoms assessed by validated questionnaire                                          178           2 capsules three times daily       3 months              5
  Cappello 2007^w31^   Italy     Secondary care   Rome II and investigations                         ≥50% improvement from baseline in overall irritable bowel syndrome symptom score using questionnaire data   57            225 mg twice daily                 4 weeks               5

Fifty two of 197 (26%) patients randomised to peppermint oil had persistent symptoms compared with 127 of 195 (65%) receiving placebo (relative risk 0.43, 0.32 to 0.59; fig 4[](#fig4){ref-type="fig"}), with statistically significant heterogeneity detected between studies (I^2^=31.1%, P=0.23). The number needed to treat with peppermint oil to prevent one patient having persistent symptoms was 2.5 (2.0 to 3.0). When only the three studies that scored 4 or more on the Jadad scale were considered in the analysis the relative risk of persistent symptoms was of a similar magnitude (0.40, 0.29 to 0.55), with no statistically significant heterogeneity detected between studies (I^2^=22.0%, P=0.28).^w30-w32^

![**Fig 4** Forest plot of randomised controlled trials of peppermint oil versus placebo in irritable bowel syndrome. Events are number of patients with either global symptoms of irritable bowel syndrome or abdominal pain unimproved or persistent after treatment](fora583237.f4){#fig4}

### Adverse events

Only three studies reported data on adverse events,^w30-w32^ and as these were few in number the data were not pooled. Five adverse events occurred among 174 patients assigned to peppermint oil compared with no adverse events in 171 patients receiving placebo.

Discussion
==========

This systematic review and meta-analysis has shown that fibre, antispasmodics, and peppermint oil are all more effective than placebo in the treatment of irritable bowel syndrome. The number needed to treat to prevent one patient having persistent symptoms was 11 for fibre, 5 for antispasmodics, and 2.5 for peppermint oil. Adverse events were significantly more frequent in those receiving antispasmodics than in those receiving placebo, but none of these was serious. As several different treatments were studied in the included randomised controlled trials, we carried out subgroup analyses.

When type of fibre was examined, wheat bran was no more effective at treating irritable bowel syndrome than placebo or a low fibre diet. The beneficial effect of fibre seemed to be limited to ispaghula husk, with a number needed to treat of 6 compared with placebo. However, significant heterogeneity was detected between trials. When only high quality studies were considered in the analysis this heterogeneity was diminished, but the difference in effect on symptoms in favour of ispaghula husk only reached marginal statistical significance.

Antispasmodics were of benefit, but again heterogeneity between study results was significant, and there was evidence of publication bias. Data were limited for many of the drugs licensed for use in the United Kingdom, such as mebeverine, dicycloverine, and alverine. It is difficult to know whether this is a true class effect of antispasmodics. Of all the drugs studied, most data were available for otilonium, trimebutine, cimetropium, hyoscine, and pinaverium. Trimebutine seemed to have no benefit over placebo in treating irritable bowel syndrome, whereas the other four drugs all significantly reduced the risk of persistent symptoms after treatment. Considerable heterogeneity was, however, detected between individual trials using otilonium and cimetropium and, although this was not the case when studies of pinaverium were pooled, the number of included patients was small. The best evidence for an individual compound seems to be for hyoscine, the efficacy of which was studied in over 400 patients. No statistically significant heterogeneity was detected, and 3.5 patients would need to be treated to prevent symptoms persisting in one patient. It would seem reasonable for general practitioners who want to begin a trial of antispasmodics to use hyoscine as first line treatment, but to consider other antispasmodics when this strategy fails.

Peppermint oil was also superior to placebo, although statistically significant heterogeneity was detected between study results, and only four randomised controlled trials were identified including fewer than 400 patients, so data were more limited than for fibre and antispasmodics. Three of these trials scored more than 4 on the Jadad scale,^w30-w32^ but the treatment effect was similar when only these studies were included in the meta-analysis, and the heterogeneity observed between studies was no longer detected.

The reporting in this systematic review adheres to the quality of reporting of meta-analyses statement.[@ref29] We have also specified the search strategy used, as well as our data extraction criteria. We believe that stating the criteria for data extraction should be standard in all systematic reviews that pool dichotomous data. The combination of our comprehensive search strategy and the translation of foreign language articles enabled us to identify studies with data from over 2500 people with irritable bowel syndrome.

Limitations of the current study arise from the quality of the studies eligible for inclusion, which in most cases was moderate to good, according to the Jadad scale. None of the included randomised controlled trials reported the method of allocation concealment, however, and as this has been shown to exaggerate treatment effect[@ref30] the numbers needed to treat with these treatments may have been overestimated. Most trials were done before the Rome committee published their recommendations for the design of randomised controlled trials of therapies in functional gastrointestinal disorders.[@ref31] Only five of the included studies used the Rome criteria to define the presence of irritable bowel syndrome,^w1\ w16\ w18\ w31\ w32^ although only nine were published after the first Rome classification was proposed in 1990,^w1\ w4\ w16\ w18\ w26\ w28\ w30-w32^ and only two used a validated outcome measure to define improvement in symptoms after treatment.^w18\ w32^ However, many of the included trials met some of the other suggested methodological criteria, such as presence of double blinding and a minimum duration of therapy of 8 to 12 weeks. We preferentially extracted patient reported improvement in symptoms of irritable bowel syndrome or abdominal pain whenever trial reporting allowed this, which is also in line with these recommendations. Blinding of patients in these studies may not have been entirely successful owing to differences in consistency and texture between fibre and placebo, adverse events experienced with antispasmodics and, in the case of peppermint oil, the smell and taste of active treatment. The pooling of data from trials to give an overall treatment effect, and a number needed to treat, could be criticised by some as a result of differences in the methodology of individual included studies. We carried out sensitivity analyses to explore reasons for heterogeneity between studies and in all cases identified potential reasons for this, while still showing a significant treatment effect for most of the treatments we assessed.

Several previous systematic reviews have examined the role of these three treatments in irritable bowel syndrome.[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] [@ref22] All of these, however, have limitations. Three reviews did not synthesise data, so no summary effect of individual treatments was reported.[@ref15] [@ref16] [@ref17] Of the five that extracted and pooled data in a meta-analysis all have numerous methodological errors,[@ref18] [@ref19] [@ref20] [@ref21] [@ref22] which render their findings potentially inaccurate. These include errors in the extraction of dichotomous data in a large proportion of included randomised controlled trials,[@ref18] [@ref19] [@ref20] [@ref21] [@ref22] inclusion of non-eligible studies (according to the investigators prespecified inclusion criteria) in four meta-analyses,[@ref18] [@ref19] [@ref20] [@ref22] incorrect handling of data from cross over studies,[@ref18] [@ref19] [@ref21] [@ref22] failure to carry out an intention to treat analysis when trial reporting allowed,[@ref19] [@ref20] [@ref21] [@ref22] incorporating studies that included patients with other functional gastrointestinal diseases in the analysis,[@ref18] [@ref20] and failure to identify eligible studies published at the time of the literature search,[@ref18] [@ref19] [@ref20] [@ref22] leading to data on truly eligible patients being excluded from the analysis. These errors led to either an overestimation or underestimation of the pooled treatment effect in many of these meta-analyses.[@ref19] [@ref20] [@ref21] [@ref22] In addition, since these reviews were carried out further randomised controlled trials of all these treatments have been published.

Current guidelines for the management of irritable bowel syndrome are equivocal or conflicting in their recommendations for the use of these treatments,[@ref11] [@ref12] [@ref23] [@ref24] but most of these have been informed by previous systematic reviews, which are potentially methodologically flawed for the reasons discussed, and this has implications for the statements made in them. In the UK, guidelines from both the National Institute for Health and Clinical Excellence and the British Society of Gastroenterology provide similar advice.[@ref11] [@ref12] Antispasmodics are recommended as first line treatment, particularly when pain and bloating are the predominant symptoms, although which of these drugs should be preferred is not stated. The use of insoluble fibre is discouraged because of concerns that it may exacerbate symptoms, an observation not borne out by our findings. Both organisations recommend that if fibre supplementation is required then this should be in the form of soluble fibres such as ispaghula. Finally, neither of these guidelines provides any statement on the role of peppermint oil in the management of irritable bowel syndrome.

The biological rationale for the efficacy of antispasmodics is unclear, but recent research using magnetic resonance imaging has shown that patients with irritable bowel syndrome and predominant diarrhoea have a reduced colon diameter as well as accelerated small bowel transit,[@ref32] so antispasmodics may act by reducing colonic contraction and transit time and therefore pain and stool frequency. Ispaghula husk may increase transit time in those with irritable bowel syndrome and predominant constipation. The efficacy of peppermint oil may arise from effects on smooth muscle, again reducing colonic contractility and pain owing to its calcium channel blocking activity.[@ref14] We were unable to examine the effect of different treatments according to predominant stool pattern reported by the patients, however, because few of the eligible trials reported these data as many predate the use of these subgroups, making it difficult to assign people to these categories retrospectively.

In summary, this systematic review and meta-analysis shows that ispaghula husk, antispasmodics (particularly hyoscine), and peppermint oil are all effective treatments for irritable bowel syndrome. Many of these are safe and available over the counter but, with the advent of newer more expensive drugs, are often overlooked as potentially effective treatments. Further large trials of these three agents in patients with irritable bowel syndrome, defined according to the Rome criteria, and using validated outcome measures are warranted. In the interim, current national guidelines for the management of the condition should be updated to include these data.

What is already known on this topic
-----------------------------------

1.  Irritable bowel syndrome is a chronic, relapsing and remitting disorder, which can be difficult to treat

2.  Safe, effective treatments are required, as newer more expensive therapies have been withdrawn because of concerns about safety

3.  Fibre, antispasmodics, and peppermint oil may fulfil this role, but evidence for their use is conflicting owing to methodological errors in previous systematic reviews

What this study adds
--------------------

1.  Fibre, antispasmodics (particularly hyoscine and otilonium), and peppermint oil were all more effective than placebo for treating irritable bowel syndrome

2.  The numbers needed to treat with these therapies were 11, 5, and 2.5, respectively

3.  Doctors should consider ispaghula, antispasmodics (preferably hyoscine as first line treatment), and peppermint oil to treat irritable bowel syndrome
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